Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Neutropenia 1Drug-Related Side Effects and Adverse Reactions 1Anemia 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Carboplatin 18Paclitaxel 13Erlotinib Hydrochloride 13Bevacizumab 13Radiotherapy 12Gemcitabine 9Pemetrexed 7Cisplatin 7Gefitinib 6Docetaxel 6Taxes 4Cetuximab 4pegfilgrastim 3Radiosurgery 2Radiation 2Nivolumab 2Neoadjuvant Therapy 2Irinotecan 2Chemotherapy, Adjuvant 2Bortezomib 2pegylated granulocyte colony-stimulating factor 1lentiviral minigene vaccine of COVID-19 coronavirus 1irofulven 1cositecan 1Watchful Waiting 1Vinorelbine 1Video-Assisted Surgery 1Topotecan 1Thalidomide 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Bronchiolo-Alveolar × 2,2'-dithiodiethanesulfonic acid × Clear all
NCT00077311 2016-06-30

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
160 enrolled
Classical hematologyThoracic

Adenocarcinoma of Lung, Anemia, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡